Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3073% below fair value
$0.18+0.00 (+0.95%)
Close on Nov 13, 2026Market cap $8.01MP/E –Yield –
Vistagen Therapeutics cash
Cash and short-term investments held at the end of each period.
Vistagen Therapeutics's cash was $20.00M at Sep 30, 2026. For fiscal 2026 it was $45.40M, down 43.6% from the year before. Over ten years it grew 59.4% a year on average. The highest annual figure on record is $119.20M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $45.40M | -43.6% |
| FY2025 | Mar 31, 2025 | $80.50M | -32.5% |
| FY2024 | Mar 31, 2024 | $119.20M | +616.4% |
| FY2023 | Mar 31, 2023 | $16.64M | -75.6% |
| FY2022 | Mar 31, 2022 | $68.14M | -33.9% |
| FY2021 | Mar 31, 2021 | $103.11M | +7508.9% |
| FY2020 | Mar 31, 2020 | $1.36M | -89.7% |
| FY2019 | Mar 31, 2019 | $13.10M | +26.2% |
| FY2018 | Mar 31, 2018 | $10.38M | +255.3% |
| FY2017 | Mar 31, 2017 | $2.92M | +581.8% |
| FY2016 | Mar 31, 2016 | $428.50K | +512.1% |
| FY2015 | Mar 31, 2015 | $70.00K | -89.0% |
| FY2013 | Mar 31, 2013 | $638.10K | +687.8% |
| FY2012 | Mar 31, 2012 | $81.00K | -41.9% |
| FY2011 | Mar 31, 2011 | $139.30K | -30.7% |
| FY2010 | Mar 31, 2010 | $201.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $20.00M | -74.1% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $31.70M | -49.8% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $45.40M | -43.6% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $61.80M | -30.2% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $77.20M | -20.9% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $63.20M | -41.7% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $80.50M | -32.5% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $88.60M | -30.0% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $97.60M | +159.5% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $108.40M | +1026.5% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $119.20M | +616.4% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $126.56M | +405.5% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $37.61M | +6.6% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $9.62M | -81.5% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $16.64M | -75.6% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $25.04M | -70.1% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $35.29M | -62.3% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $51.99M | -46.8% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $68.14M | -33.9% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $83.70M | -19.8% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $93.63M | +508.0% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $97.78M | +6224.9% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $103.11M | +7508.9% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $104.33M | +9712.0% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $15.40M | +278.1% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $1.55M | -81.4% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $1.36M | -89.7% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $1.06M | -83.1% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $4.07M | -48.0% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $8.30M | +14.7% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $13.10M | +26.2% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $6.29M | -51.8% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $7.83M | +343.9% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $7.23M | +344.1% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $10.38M | +255.3% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $13.03M | +198.1% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $1.76M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $1.63M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $2.92M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $4.37M | – |
See a number that looks wrong?